A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

Inclusion Criteria:

• Unequivocal histologically or cytologically confirmed diagnosis of metastatic orlocally advanced NSCLC not amenable to treatment with surgical resection or combinedchemoradiation

• Disease progression during or after treatment with at least one prior systemictherapy but no more than three lines of prior systemic therapy in the advanced ormetastatic setting

• Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

• Documentation of the presence of a KRAS G12C mutation

• Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumorspecimen in a paraffin block (preferred) or 10-15 (15 preferred) unstained, freshlycut, serial slides with an associated pathology report

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Life expectancy of >= 12 weeks

Exclusion Criteria:

• Known hypersensitivity to any of the components of divarasib, or sotorasib oradagrasib

• Malabsorption syndrome or other condition that would interfere with enteralabsorption

• Known concomitant second oncogenic driver

• Mixed small-cell lung cancer or large cell neuroendocrine histology

• Known and untreated, or active central nervous system (CNS) metastases

• Leptomeningeal disease or carcinomatous meningitis

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrentdrainage procedures biweekly or more frequently

• Any infection that, in the opinion of the investigator, could impact patient safety,or treatment with therapeutic oral or IV antibiotics within 14 days prior to Day 1of Cycle 1

• Prior treatment with any KRAS G12C inhibitor or pan-KRAS/RAS inhibitor

• More than 30 Gy of radiotherapy to the lung within 6 months of randomization

• Uncontrolled tumor-related pain

• Unresolved toxicities from prior anticancer therapy

• History of malignancy within 5 years prior to screening, with the exception of thecancer under investigation in this study and malignancies with a negligible risk ofmetastasis or death (e.g., 5-year OS rate >90%), such as adequately treatedcarcinoma in situ of the cervix, nonmelanoma skin carcinoma, localized prostatecancer, ductal carcinoma in situ, or Stage I uterine cancer